HLA expression in cancer: Implications for T cell-based immunotherapy

Immunogenetics

Volumn 53, Issue 4, 2001, Pages 255-263

  Sette, A ^a   Chesnut, R ^a   Fikes, J ^a  

^a Epimmune   (United States)

Author keywords

Class I; Epitope; HLA; Immunotherapy; Tumor

Indexed keywords

HLA ANTIGEN CLASS 1;

ANTIGEN EXPRESSION; ARTICLE; CANCER CLASSIFICATION; CANCER IMMUNOTHERAPY; CYTOKINE RELEASE; DISEASE COURSE; HISTOPATHOLOGY; HLA SYSTEM; HUMAN; IMMUNOHISTOCHEMISTRY; INFLAMMATION; NATURAL KILLER CELL; PREDICTION; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TUMOR DIFFERENTIATION;

ANTIGENS, NEOPLASM; GENE EXPRESSION; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOTHERAPY; NEOPLASMS; T-LYMPHOCYTES;

EID: 0034911610     PISSN: 00937711     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002510100334     Document Type: Article

References (56)

1. The HLA crossroad in tumor immunology
2. MHC class I and II expression in prostate carcinoma and modulation by interferon-alpha and -gamma
3. Expression of differentiation - Related genes in colorectal cancer: Possible implications for prognosis
4. Loss of HLA class I expression in prostate cancer: Implications for immunotherapy
5. Minimal requirements for peptide mediated activation of CD8+ CTL
6. Mechanisms of loss of HLA class I expression on colorectal tumor cells
7. Low numbers of MHC class I-peptide complexes required to trigger a T cell response
8. Flt3-ligand induces transient tumor regression in an ectopic treatment model of major histocompatibility complex-negative prostate cancer
9. Can the HLA phenotype be used as a prognostic factor in breast carcinomas?
10. Antitumor immunity at work in a melanoma patient
11. Loss of transporter protein, encoded by the TAP-1 gene, is highly correlated with loss of HLA expression in cervical carcinomas
12. A comparison of flow cytometry and immunohistochemistry in human colorectal cancers
13. Association of allele-specific HLA expression and histopathologic progression of cervical carcinoma
14. Level of HLA antigens in locoregional metastases and clinical course of the disease in patients with melanoma
15. MHC class I antigens and tumour-infiltrating leucocytes in laryngeal cancer: Long-term follow-up
16. Loss of HLA class I antigens by melanoma cells: Molecular mechanisms, functional significance and clinical relevance
17. Natural history of HLA expression during tumour development
18. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours
19. Major histocompatibility complex class I and class II expression in renal cell carcinoma and modulation by interferon gamma
20. Loss of monomorphic and polymorphic HLA antigens in metastatic breast and colon carcinoma
21. Local T cell responses induce widespread MHC expression: Evidence that IFN-gamma induces its own expression in remote sites
22. The expression of histocompatibility-related leukocyte antigens in the pathway to cervical carcinoma
23. Loss of HLA haplotype in lung cancer cell lines: Implications for immunosurveillance of altered HLA class I/II phenotypes in lung cancer
24. Microsatellite instability analysis in tumors with different mechanisms for total loss of HLA expression
25. MHC loss in colorectal tumours: Evidence for immunoselection?
26. Loss of HLA class-I alleles, heavy chains and beta 2-microglobulin in colorectal cancer
27. Loss of transporter in antigen processing 1 transport protein and major histocompatibility complex class I molecules in metastatic versus primary breast cancer
28. HLA class I antigen expression in human solid tumors
29. HLA class I phenotype and genotype alterations in cervical carcinomas and derivative cell lines
30. Multiple genetic alterations cause frequent and heterogeneous human histocompatibility leukocyte antigen class I loss in cervical cancer
31. Interferon-γ-induced ICAM-1 and CD40 expression, complete lack of HLA-DR and CD80 (B7.1), and inconsistent HLA-ABC expression in basal cell carcinoma: A possible role for interleukin-10?
32. Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer
33. Host resistance directed selectively against H-2 deficient lymphoma variants: Analysis of the mechanism
34. Decreased HLA-A expression in prostate cancer is associated with normal allele dosage in the majority of cases
35. Prognostic significance of T-cell infiltrates, expression of β2-microglobulin and HLA-DR antigens in breast carcinoma
36. Reduction in susceptibility to natural killer cell-mediated lysis of human FO-1 melanoma cells after induction of HLA class I antigen expression by transfection with B2m gene
37. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1
38. The role of surface HLA-A, B, C molecules in tumour immunity
39. Distribution of human class I (HLA-A,B,C) histocompatibility antigens in normal and malignant tissues of nonlymphoid origin
40. Heterogeneity in expression of human leukocyte antigens and melanoma-associated antigens in advanced melanoma
41. HLA-G expression in melanoma: A way for tumor cells to escape from immunosurveillance
42. Interferons and their actions
43. Expression of HLA class I and II antigens in bronchogenic carcinomas: Its relationship to cellular DNA content and clinical-pathological parameters
44. Class I major histocompatibility complex antigens and tumor ploidy in breast and bronchogenic carcinomas
45. Lack of correlation between codon 12 K-ras mutations and major histocompatibility complex antigens in bronchogenic carcinomas
46. Selective MHC expression in tumours modulates adaptive and innate antitumour responses
47. Loss of polymorphic A and B locus HLA antigens in colon carcinoma
48. 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy
49. Immune selection after antigen-specific immunotherapy of melanoma
50. Perforin and IFN-gamma are involved in the antitumor effects of antibody-targeted superantigens
51. Molecular characterization of defective antigen processing in human prostate cancer
52. Relationship between myc oncogene activation and MHC class I expression
53. Expression of MHC class I and class II antigens in pancreatic adenocarcinomas
54. Evidence that a single peptide-MHC complex on a target cell can elicit acytolytic T cell response
55. HLA class I expression on human cancer cells: Implications for effective immunotherapy
56. Loss of an HLA haplotype in pancreas cancer tissue and its corresponding tumor derived cell line